These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22507524)

  • 1. Haemophilia prophylaxis: how can we justify the costs?
    Feldman BM; Berger K; Bohn R; Carcao M; Fischer K; Gringeri A; Hoots K; Mantovani L; Willan AR; Schramm W
    Haemophilia; 2012 Sep; 18(5):680-4. PubMed ID: 22507524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drugs to treat hemophilia.
    Valentino LA; Ismael Y; Grygotis M
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):597-613. PubMed ID: 20653467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.
    Majumdar S; Ostrenga A; Latzman RD; Payne C; Hunt Q; Morris A; Iyer R
    Haemophilia; 2011 Jul; 17(4):717-8. PubMed ID: 21323798
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
    Walsh CE; Valentino LA
    Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    J Intern Med; 1998 Dec; 244(6):515-22. PubMed ID: 9893105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hemophilia with minimal factor replacement in developing countries: role of ancillary therapy.
    Chandy M
    Semin Thromb Hemost; 2005 Nov; 31(5):501-6. PubMed ID: 16276457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia.
    Miners AH; Lee CA
    Haemophilia; 2004 Mar; 10 Suppl 1():58-62. PubMed ID: 14987250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review.
    Khleif AA; Rodriguez N; Brown D; Escobar MA
    Haemophilia; 2012 May; 18(3):e95-e100. PubMed ID: 21910793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal haemophilia care versus the reality.
    Bolton-Maggs PH
    Br J Haematol; 2006 Mar; 132(6):671-82. PubMed ID: 16487168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between prophylaxis and on demand treatment for severe haemophilia.
    Khoriaty R; Taher A; Inati A; Lee C
    Clin Lab Haematol; 2005 Oct; 27(5):320-3. PubMed ID: 16178913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia in the managed care setting.
    Dalton DR
    Am J Manag Care; 2015 Mar; 21(6 Suppl):S123-30. PubMed ID: 26168207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tertiary prophylaxis in adults: is there a rationale?
    Gringeri A; Lambert T; Street A; Aledort L;
    Haemophilia; 2012 Sep; 18(5):722-8. PubMed ID: 22639786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a partnership of care for patients with haemophilia.
    Carnahan M
    N Z Med J; 2003 Dec; 116(1187):U721. PubMed ID: 14752544
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic aspects of haemophilia care.
    Aldedort LM; Miners A; Bohn R; Borrero P; Goudemand J; Hoots K; Kavakli K; Lee C; Roberts J; Schramm W; Szucs T; Wasserman J
    Haemophilia; 1999 May; 5(3):216-9. PubMed ID: 10484669
    [No Abstract]   [Full Text] [Related]  

  • 18. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia.
    Rogoff EG; Guirguis HS; Lipton RA; Seremetis SV; DiMichele DM; Agnew GM; Karpatkin M; Barish RJ; Jones RL; Bianco C; Knothe BD; Lee MS
    Thromb Haemost; 2002 Oct; 88(4):545-53. PubMed ID: 12362223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High cost, low volume care: the case of haemophilia.
    Lee C; Sabin C; Miners A
    BMJ; 1997 Oct; 315(7114):962-3. PubMed ID: 9365285
    [No Abstract]   [Full Text] [Related]  

  • 20. Health economics of treating haemophilia A with inhibitors.
    Knight C
    Haemophilia; 2005 Nov; 11 Suppl 1():11-7. PubMed ID: 16219044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.